# 神经生物标志物市场

> 神经生物标志物市场研究报告按应用（阿尔茨海默病、帕金森病、多发性硬化症、中风、癫痫）、按类型（遗传生物标志物、蛋白质组学生物标志物、代谢组学生物标志物、影像生物标志物）、按最终用户（制药公司、临床实验室、研究机构、合同研究组织）、按技术（生物分子分析、影像技术、基因组测序、蛋白质组学）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 预测到2035年。

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.24%
- **2024:** $ 5.04 Billion
- **2025:** $ 5.3 Billion
- **2035:** $ 8.83 Billion
- **Key Players:** Roche (CH), AbbVie(US), Biogen (US), Eli Lilly (US), Novartis (CH), Amgen (US), Merck (DE), Pfizer (US), AstraZeneca (GB)

**Report ID:** MRFR/HC/32076-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/neurological-biomarker-market-33914

---

## Market Summary

## **Neurological Biomarker Market Overview**

As per MRFR analysis, the Neurological Biomarker Market Size was estimated at 5.04 (USD Billion) in 2024. The Neurological Biomarker Market Industry is expected to grow from 5.30 (USD Billion) in 2025 to 8.39 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.24% during the forecast period (2025 - 2034).

### **Key Neurological Biomarker Market Trends Highlighted**

The Global Neurological Biomarker Market is experiencing significant growth driven by the rising prevalence of neurological disorders and advancements in biomarker discovery technologies. There is an increasing demand for precise diagnostic tools and therapeutic strategies that can lead to early detection and better management of conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Increased awareness about neurological diseases and the importance of biomarkers is helping to propel this market forward. Additionally, the emphasis on personalized medicine is fueling investment in research and development, leading to the advent of novel biomarkers that can improve patient outcomes.

Opportunities in the market arise from the integration of artificial intelligence and machine learning in biomarker research.

These technologies can analyze vast amounts of data, revealing patterns that assist in identifying new biomarkers and enhancing diagnostic accuracy. Furthermore, collaborations among research institutions, diagnostic companies, and pharmaceutical firms can result in innovative solutions that capitalize on the need for effective biomarker-based tools in clinical settings. 

The growing trend of home healthcare and telemedicine also opens new avenues for the deployment of neurological biomarkers in remote patient monitoring.Recent trends indicate a focus on developing biomarkers that can track disease progression and response to therapy, which can provide healthcare professionals with essential information for treatment adjustments. The exploration of neuroimaging techniques and the utilization of blood-based biomarkers are also gaining traction, promising to enhance diagnostic capabilities. The market is witnessing a gradual shift toward non-invasive approaches, reflecting a broader industry trend aimed at improving patient comfort and compliance.

Overall, the Global Neurological Biomarker Market is poised for a transformative phase fueled by innovation, collaboration, and an evolving understanding of neurological diseases.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Neurological Biomarker Market Drivers**

### **Increasing Prevalence of Neurological Disorders**

The Global Neurological Biomarker Market Industry is experiencing substantial growth, primarily driven by the rising incidence of neurological disorders such as [Alzheimer's disease](../../../reports/alzheimers-disease-diagnostic-market-2149), Parkinson's disease, and multiple sclerosis. As the global population ages, the number of individuals affected by these debilitating conditions is on the rise, leading to an increased demand for early diagnosis and effective treatment options. Neurological biomarkers play a crucial role in this context, as they aid in identifying the presence of neural dysfunction at a molecular level.By facilitating early detection, biomarkers enable timely interventions, which can significantly enhance patient outcomes.

Additionally, advancements in genomic and proteomic technologies are unlocking new avenues for research and development in biomarker discovery, further expanding the scope of their application in clinical settings. As healthcare systems worldwide shift towards personalized medicine, the focus on understanding individual patient profiles through biomarkers is expected to grow, thus propelling the market for neurological biomarkers.Consequently, the need for innovative and precise diagnostic tools to manage neurological disorders paves the way for significant investments in the Global Neurological Biomarker Market Industry, ensuring continued advancements in the field.

### **Technological Advancements in Biomarker Discovery**

The Global Neurological Biomarker Market Industry is significantly benefitting from rapid technological advancements in biomarker discovery methodologies. Innovations in fields such as genomics, proteomics, and metabolomics are leading to the development of more sensitive and specific biomarkers. These technologies enable researchers to uncover new biomarkers that can predict disease onset, monitor disease progression, and evaluate treatment responses more effectively.As these advanced tools become integrated into clinical practice, they are expected to drastically improve the accuracy of neurological assessments, driving demand in the biomarker market.

### **Rise in Research and Development Activities**

The Global Neurological Biomarker Market Industry is witnessing a surge in research and development activities, fueled by an increased focus on neurological health. Government and private sector initiatives aimed at funding and supporting research projects related to biomarker identification and validation are playing a pivotal role in this growth. This not only aids in the discovery of new biomarkers for various neurological disorders but also encourages collaboration between academic institutions, biotech companies, and pharmaceutical firms.As research progresses, it is likely to lead to the introduction of novel biomarkers into the market, thereby enhancing diagnostic capabilities and treatment personalization for patients.

## **Neurological Biomarker Market Segment Insights**

### **Neurological Biomarker Market Application Insights**

The Global Neurological Biomarker Market segment focused on Applications has shown considerable growth and importance in the healthcare landscape as of 2023. With a total market revenue of 4.55 USD Billion, the Application segment is further divided into specific conditions such as Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Stroke, and Epilepsy.

Alzheimer's Disease currently holds a prominent position, valued at 1.5 USD Billion in 2023, and is projected to rise to 2.4 USD Billion by 2032, showcasing a significant demand for innovative diagnostics and therapies in tackling this neurodegenerative disorder. The prominence of this segment is largely attributed to the increasing prevalence of Alzheimer's, which is becoming a major public health concern, reflecting its popularity in the Global Neurological Biomarker Market data.

Similarly, the Parkinson's Disease segment holds a value of 0.9 USD Billion in 2023 and is expected to grow to 1.5 USD Billion by 2032. This growth signifies the escalating research and development efforts aimed at understanding and managing symptoms of Parkinson's, making it a significant area within the Global Neurological Biomarker Market statistics.

Multiple Sclerosis, valued at 0.8 USD Billion in 2023, is another critical segment showing projected growth to 1.2 USD Billion by 2032, emphasizing the need for biomarkers to improve diagnosis and treatment options, as this condition predominantly affects adolescents and young adults.

Meanwhile, Stroke is valued at 0.95 USD Billion in 2023 and is anticipated to reach 1.65 USD Billion by 2032, demonstrating its importance in urgent patient care and the necessity for rapid diagnostic tools.The stroke segment's growth is driven by an increasing number of stroke incidents globally, highlighting the urgent healthcare need it addresses.

Lastly, the Epilepsy segment, currently valued at 0.4 USD Billion and growing to 0.66 USD Billion by 2032, shows a more modest yet notable impact in the market. The significance of neurological biomarkers related to epilepsy lies in the development of personalized medicine approaches, particularly in determining treatment efficacy for patients.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Neurological Biomarker Market Type Insights**

The Global Neurological Biomarker Market is evolving rapidly, with a projected value of 4.55 billion USD in 2023, aimed to reach 7.21 billion USD by 2032. The market segmentation by Type includes Genetic Biomarkers, Proteomic Biomarkers, Metabolomic Biomarkers, and Imaging Biomarkers. Genetic Biomarkers play an essential role in the early detection of various neurological diseases and hold significant potential in personalized medicine. Proteomic Biomarkers are crucial for understanding the pathological processes and identifying potential therapeutic targets, thereby driving the market growth.Metabolomic Biomarkers contribute to insights about disease progression and can aid in monitoring treatment responses.

Imaging Biomarkers are also increasingly significant due to advancements in neuroimaging technologies, allowing for enhanced disease diagnosis and management.

The market growth is supported by rising incidences of neurological disorders, increasing demand for precise diagnostics, and advancements in biomarker discovery techniques. However, challenges such as high developmental costs and stringent regulatory requirements may impact progress.Overall, the diversification in the Global Neurological Biomarker Market segmentation points to a comprehensive landscape with ample opportunities for research and development in the coming years.

### **Neurological Biomarker Market End User Insights**

The Global Neurological Biomarker Market has demonstrated significant potential, with a market valuation of 4.55 billion USD in 2023, reflecting its growing importance across various end-user segments. In this market landscape, Pharmaceutical Companies play a crucial role as they utilize neurological biomarkers to enhance drug development processes for neurological disorders. Clinical Laboratories also significantly contribute, offering essential diagnostic services that leverage these biomarkers for accurate disease identification and management.Research Institutions are pivotal in advancing the Global Neurological Biomarker Market data, conducting studies that lead to innovative biomarker discoveries and applications.

Additionally, Contract Research Organizations (CROs) support the market by providing specialized services that enable efficient and effective clinical trials, essential for new drug approvals. 

As the market expands towards a projected value of 7.21 billion USD by 2032, trends such as increasing investments in neurodegenerative disease research and advancements in biomarker technology are driving growth.However, challenges, including regulatory hurdles and the need for standardization, can impact market dynamics despite the promising opportunities that persist in this evolving industry. Overall, the Global Neurological Biomarker Market segmentation reflects a diverse and robust ecosystem crucial for addressing neurological health challenges.

### **Neurological Biomarker Market Technology Insights**

The Global Neurological Biomarker Market, particularly within the Technology segment, is significantly shaping the diagnostics and treatment landscape. In 2023, the market was valued at 4.55 billion, reflecting a growing recognition of the importance of neurological biomarkers in understanding disorders.

This Technology segment encompasses various crucial aspects such as Biomolecular Analysis, which facilitates the identification of disease markers, and Imaging Techniques that enhance visual interpretations of neurological conditions.

Genomic Sequencing is another critical component underpinning personalized medicine by offering insights into genetic predispositions to neurological diseases.Proteomics plays a significant role as it supports the analysis of protein expressions associated with neurological disorders, providing insights that are critical for developing targeted therapies.

The integration of these technologies not only drives market growth but also enhances the overall understanding of complex neurological conditions, contributing to better patient outcomes. The market, with a projected valuation of 7.21 billion by 2032, indicates a robust expansion driven by innovations and the increasing prevalence of neurological disorders.

### **Neurological Biomarker Market Regional Insights**

The Global Neurological Biomarker Market has shown a diverse array of valuations across its regional segments, with North America leading significantly at a valuation of 2.1 USD Billion in 2023, expected to reach 3.3 USD Billion by 2032. This region dominates largely due to advanced healthcare infrastructure and increased investment in research.

Europe followed with a valuation of 1.2 USD Billion in 2023, projected to grow to 1.9 USD Billion, driven by rising awareness of neurological disorders and the need for innovative diagnostic solutions. The APAC region presents a market value of 0.85 USD Billion in 2023, anticipated to grow to 1.35 USD Billion, reflecting a growing focus on healthcare advancements in emerging economies.South America and MEA have comparatively lower valuations at 0.25 USD Billion and 0.15 USD Billion, respectively, in 2023, with expected increases to 0.4 USD Billion and 0.26 USD Billion by 2032.

However, these regions offer significant growth potential due to increasing healthcare investments and collaborative initiatives for research and development. Overall, regional disparities highlight the importance of tailored market strategies to capitalize on local growth opportunities within the Global Neurological Biomarker Market industry.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Neurological Biomarker Market Key Players and Competitive Insights**

The Global Neurological Biomarker Market is characterized by a diverse range of players who are leveraging advanced technologies and innovations to deliver next-generation diagnostic solutions. The market comprises numerous companies, both established and emerging, which are collectively focused on enhancing the understanding of neurological conditions through biomarker discovery and validation. Advanced research methodologies combined with sophisticated technology platforms have enabled these companies to foster substantial progress in identifying biomarkers associated with various neurological disorders.Siemens Healthineers stands out in the Global Neurological Biomarker Market with its strong technological infrastructure and commitment to research and development. 

The company has established a significant market presence through its advanced imaging and diagnostic solutions that cater specifically to neurological disorders. With an emphasis on accuracy and reliability, Siemens Healthineers has developed diagnostic technologies that aid in the early detection of conditions such as Alzheimer's disease and other neurodegenerative disorders.

Their dedication to innovation is demonstrated through ongoing partnerships and collaborations with healthcare providers and research institutions, allowing them to stay at the forefront of the evolving landscape in neurological biomarkers.AstraZeneca plays a crucial role within the Global Neurological Biomarker Market by focusing on the development of innovative therapeutics and companion diagnostics for neurological disorders.

The company's robust portfolio is complemented by its significant investment in research initiatives aimed at unlocking the complexities of neurological diseases through biomarker identification. AstraZeneca's collaboration with academic institutions and biotechnology firms enables it to enhance its capabilities in biomarker discovery, facilitating the development of targeted therapies and personalized treatment plans. The company's strengths include a strong emphasis on scientific exploration and a commitment to integrating biomarker research into clinical practice, which supports the drive toward precision medicine.

### **Key Companies in the Neurological Biomarker Market Include**

- [Siemens Healthineers](https://www.siemens-healthineers.com/laboratory-diagnostics/assays-by-diseases-conditions/neurology-assays)
- AstraZeneca
- GSK
- Eli Lilly and Company
- Abbott Laboratories
- Medtronic
- Takeda Pharmaceutical
- Thermo Fisher Scientific
- Merck Group
- Pfizer
- Biogen
- Johnson and  Johnson
- Roche
- Novartis
- Amgen

## Neurological Biomarker Market Industry Developments

- **Q2 2024: Quanterix Launches Simoa® p-Tau 217 Advantage V2 Kit to Advance Alzheimer’s Disease Research** Quanterix announced the launch of its Simoa® p-Tau 217 Advantage V2 Kit, a next-generation neurological biomarker assay designed to improve the detection of Alzheimer’s disease pathology in blood samples.
- **Q2 2024: C2N Diagnostics Announces CE Mark for PrecivityAD2™ Blood Test for Alzheimer’s Disease** C2N Diagnostics received CE Mark approval for its PrecivityAD2™ blood test, enabling its commercial launch in Europe for the detection of Alzheimer’s disease biomarkers.
- **Q2 2024: Alto Neuroscience Raises $45 Million in Series C Financing to Advance Precision Psychiatry Platform** Alto Neuroscience secured $45 million in Series C funding to accelerate the development of its biomarker-driven platform for neurological and psychiatric disorders.
- **Q1 2024: Olink launches new neurology biomarker panel for high-throughput proteomics** Olink introduced a new neurology biomarker panel, expanding its high-throughput proteomics offering to support neurological disease research and drug development.
- **Q1 2024: Neurotrack and Quest Diagnostics Announce Strategic Partnership to Advance Early Detection of Cognitive Decline** Neurotrack and Quest Diagnostics formed a partnership to develop and commercialize digital and blood-based neurological biomarker tests for early detection of cognitive impairment.
- **Q2 2024: Diadem Receives FDA Breakthrough Device Designation for AlzoSure® Predict Blood Test for Alzheimer’s Disease** Diadem announced that its AlzoSure® Predict blood test for early detection of Alzheimer’s disease received Breakthrough Device Designation from the U.S. FDA.
- **Q2 2024: Amprion Receives FDA Breakthrough Device Designation for SYNTap Biomarker Test for Parkinson’s Disease** Amprion’s SYNTap Biomarker Test, designed to detect synucleinopathies such as Parkinson’s disease, was granted Breakthrough Device Designation by the FDA.
- **Q1 2024: Quanterix Appoints Masoud Toloue as Chief Executive Officer** Quanterix announced the appointment of Masoud Toloue as its new CEO, aiming to drive growth in the neurological biomarker sector.
- **Q2 2024: Cerveau Technologies and Eisai Enter Collaboration to Advance Tau PET Imaging Biomarker Research** Cerveau Technologies and Eisai announced a collaboration to advance research and development of tau PET imaging biomarkers for neurodegenerative diseases.
- **Q1 2024: Alzheon Announces $100 Million Series D Financing to Advance ALZ-801 and Biomarker Programs** Alzheon raised $100 million in Series D funding to support late-stage clinical development of ALZ-801 and expansion of its neurological biomarker programs.
- **Q2 2024: NeuroSense Therapeutics Receives FDA Orphan Drug Designation for PrimeC in ALS** NeuroSense Therapeutics received FDA Orphan Drug Designation for PrimeC, a therapy for ALS, which is supported by biomarker-driven clinical development.
- **Q1 2024: Alector and GSK Announce Strategic Collaboration to Develop Novel Neurodegeneration Biomarkers** Alector and GSK entered a strategic collaboration to develop and commercialize novel biomarkers for neurodegenerative diseases.

## **Neurological Biomarker Market Segmentation Insights**

### **Neurological Biomarker Market Application Outlook**

- Alzheimer's Disease
- Parkinson's Disease
- Multiple Sclerosis
- Stroke
- Epilepsy

### **Neurological Biomarker Market Type Outlook**

- Genetic Biomarkers
- Proteomic Biomarkers
- Metabolomic Biomarkers
- Imaging Biomarkers

### **Neurological Biomarker Market End User Outlook**

- Pharmaceutical Companies
- Clinical Laboratories
- Research Institutions
- CROs

### **Neurological Biomarker Market Technology Outlook**

- Biomolecular Analysis
- Imaging Techniques
- Genomic Sequencing
- Proteomics

### **Neurological Biomarker Market Regional Outlook**

- North America
- Europe
- South America
- Asia-Pacific
- Middle East and Africa ** **

## Market Drivers

### 生物标志物技术的进展

生物标志物发现和验证中的技术创新正在改变神经生物标志物市场的格局。高通量筛选方法、下一代测序和先进成像技术的出现显著增强了识别和表征神经生物标志物的能力。这些进展促进了更准确和可靠的诊断工具的发展，这对于及时识别神经系统疾病至关重要。因此，神经生物标志物市场正在涌现出大量新型生物标志物，这些生物标志物可以改善患者的治疗结果并简化临床工作流程。人工智能和机器学习在生物标志物分析中的整合进一步增强了这一趋势，预示着该行业的光明未来。

### 增加对研究和开发的投资

神经生物标志物市场受益于对研发活动的加大投资。制药公司和研究机构越来越多地分配资源，以探索能够帮助诊断和治疗神经系统疾病的新型生物标志物。这一趋势通过大量资金用于临床试验和生物标志物验证研究得到了证明。2023年，神经学领域的研发支出约为300亿美元，反映出对推进神经学研究的日益承诺。这些投资可能会产生创新的生物标志物，从而提高诊断准确性和治疗效果，推动神经生物标志物市场的增长。

### 生物标志物开发的监管支持

监管机构在促进神经生物标志物市场的增长中发挥着至关重要的作用，提供支持生物标志物开发和验证的框架。旨在加快生物标志物审批流程的举措正在鼓励制药公司在这一领域进行投资。例如，FDA已建立程序，促进生物标志物在药物开发和临床试验中的资格认证。这种监管支持不仅加速了新生物标志物进入市场的进程，还增强了这些工具在医疗专业人士中的可信度。因此，随着更多经过验证的生物标志物可供临床使用，神经生物标志物市场可能会扩大。

### 神经系统疾病的发病率上升

神经系统疾病（如阿尔茨海默病、帕金森病和多发性硬化症）发病率的不断上升是神经生物标志物市场的主要驱动因素。根据最近的估计，受这些疾病影响的个体数量预计将显著增加，仅阿尔茨海默病预计到2050年将影响超过1400万人。这种流行率的激增需要开发有效的诊断工具和治疗方案，从而推动对神经生物标志物的需求。随着医疗系统努力管理这些日益增长的患者群体，神经生物标志物市场可能会经历显著增长，推动因素是对早期检测和个性化治疗策略的需求。

### 对个性化医疗的需求日益增长

个性化医疗的转变正在显著影响神经生物标志物市场。随着医疗保健逐渐摆脱一刀切的方法，越来越强调根据个体患者的特征量身定制治疗。神经生物标志物在这一范式转变中发挥着关键作用，使临床医生能够识别特定的疾病亚型并预测治疗反应。预计未来几年神经学个性化医疗市场的复合年增长率将超过10%。这一趋势突显了生物标志物在开发靶向疗法中的重要性，从而推动了神经生物标志物市场的需求。

## Future Outlook

神经生物标志物市场预计将在2024年至2035年间以5.24%的年均增长率增长，推动因素包括诊断技术的进步、神经系统疾病的发病率增加以及医疗投资的上升。

**New opportunities:**

- 针对性治疗的个性化生物标志物面板的开发。 在生物标志物发现过程中整合人工智能驱动的分析。 扩展远程医疗服务以进行远程生物标志物监测。

到2035年，神经生物标志物市场预计将强劲增长，反映出显著的增长和创新。

## Segment Insights

### 按应用：阿尔茨海默病（最大）与帕金森病（增长最快）

在神经生物标志物市场中，阿尔茨海默病作为主导应用领域，因其在全球范围内日益普遍而占据最大份额。紧随其后，帕金森病正在获得动力，反映出其作为增长最快的细分市场的角色，受到意识提升和诊断进展的推动。其他应用如多发性硬化症、中风和癫痫也贡献了可观的份额，但目前被阿尔茨海默病相关生物标志物的显著需求所掩盖。神经生物标志物市场的增长趋势受到多种因素的推动，包括老龄化人口、生物标志物发现的进展，以及对神经系统疾病早期诊断的重视。研发投资至关重要，尤其是在阿尔茨海默病和帕金森病方面，持续的创新促进了新的检测选项和治疗方法，提升了生活质量并应对系统性医疗挑战。

阿尔茨海默病（显性）与帕金森病（新兴）

阿尔茨海默病是神经生物标志物市场的基石，因为它涵盖了一系列对诊断和疾病进展监测至关重要的生物标志物。该细分市场受益于大量的研究资金和对早期检测需求的日益关注。阿尔茨海默病生物标志物已得到充分确立，为临床医生提供了可靠的框架。与此同时，帕金森病代表了一个新兴细分市场，受到临床试验和生物标志物技术创新的推动。该细分市场的特点是关注神经炎症及其与疾病进展的相关性，使其成为一个集中的研究和开发领域。随着诊断选项变得更加复杂，帕金森病生物标志物在神经退行性疾病研究中获得了关注，补充了已建立的阿尔茨海默病指标，并揭示了量身定制治疗策略的迫切需求。

### 按类型：遗传生物标志物（最大）与影像生物标志物（增长最快）

神经生物标志物市场反映了包括遗传、生物蛋白组、代谢组和影像生物标志物在内的多样化细分价值。在这些细分中，遗传生物标志物由于在识别神经系统疾病的遗传易感性方面的关键作用，拥有最大的市场份额。它们被广泛用于制定个性化治疗方案。影像生物标志物虽然目前是一个较小的细分市场，但随着技术进步提高了其准确性和可靠性，正在迅速获得关注，导致临床诊断和研究中的需求增加。

遗传生物标志物（主导）与影像生物标志物（新兴）

基因生物标志物因其能够提供关于神经系统疾病的遗传易感性的重要见解，从而在神经生物标志物市场中确立了主导地位，帮助早期诊断和量身定制的治疗。同时，成像生物标志物以其非侵入性特征和如MRI和PET扫描等尖端技术，正在成为一个重要参与者。对实时可视化大脑变化的关注增加，以及人工智能在成像分析中的整合，正在推动其快速增长。这些动态正在重塑神经诊断的格局，两者在改善患者结果方面发挥着互补的作用。

### 按最终用户：制药公司（最大）与临床实验室（增长最快）

神经生物标志物市场的特点是终端用户种类繁多，主要包括制药公司、临床实验室、研究机构和合同研究组织（CRO）。在这些用户中，制药公司占据了最大的市场份额，利用其在生物标志物开发方面的丰富资源和能力。相比之下，临床实验室正在迅速获得关注，越来越多地采用神经生物标志物来增强其诊断产品并改善患者结果。增长趋势表明，制药公司专注于创新药物发现和个性化医疗，推动了对神经生物标志物的需求。另一方面，临床实验室受益于技术进步和对神经疾病认识的提高，正将自己定位为这一不断发展的市场中的关键参与者。研究机构和CRO也在增长中发挥作用，尽管速度较慢，主要专注于合作和研究计划。

制药公司（主导）与临床实验室（新兴）

制药公司目前是神经生物标志物市场的主导力量，利用其庞大的财务资源和研发能力开发针对性的疗法。它们的既定地位使其在临床试验和监管审批中处于领先地位，从而获得竞争优势。相比之下，临床实验室作为重要参与者正在崛起，因为它们在诊断过程中的角色变得越来越关键。随着技术的进步，这些实验室正在扩展其服务，以包括对神经疾病的更全面检测。个性化医疗的推动也在影响这一转变，因为临床实验室适应以提供量身定制的解决方案。这两个领域共同体现了一个动态的格局，其中既有成熟的实体，也有新兴的实体共存并蓬勃发展。

### 按技术：生物分子分析（最大）与成像技术（增长最快）

神经生物标志物市场受到各种技术进步的显著影响。生物分子分析在这一领域中占据主导市场份额，主要得益于其成熟的方法论和在诊断神经系统疾病中的广泛应用。利用各种生物分子进行疾病识别和监测增强了其地位，使其成为神经研究和临床应用中的重要领域。影像技术虽然目前占有较小的市场份额，但随着先进MRI技术和功能成像等创新的出现，正在迅速崛起，承诺改善神经疾病的诊断和治疗方案。

生物分子分析（主导）与成像技术（新兴）

生物分子分析的特点在于利用生物分子来识别和评估神经系统疾病。其主导地位归因于成熟的协议和在临床环境中的接受度。该领域涵盖了多种涉及蛋白质、酶和核酸的技术，以有效提供对神经系统状况的洞察。另一方面，成像技术则拥有创新的技术，如MRI和PET扫描，这些技术在理解大脑功能和识别疾病方面变得至关重要。尽管仍在发展中，但由于对准确诊断的需求不断增加以及持续的技术进步，这些技术正在迅速获得关注，为更高效的成像解决方案铺平道路。

## Regional Market Share Analysis

### 北美：引领创新与研究

北美是神经生物标志物最大的市场，约占全球市场份额的45%。该地区受益于先进的医疗基础设施、显著的研发投资以及神经疾病日益增加的发病率。FDA等机构的监管支持加速了创新生物标志物测试的批准，推动了市场增长。对个性化医疗和早期诊断的日益关注进一步推动了对这些生物标志物的需求。美国是该市场的主要贡献者，罗氏、艾伯维和生物基因等关键企业引领着这一领域。竞争格局由一系列成熟的制药巨头和新兴的生物技术公司组成。加拿大也发挥着重要作用，越来越重视研究合作和临床试验，增强了整体市场动态。

### 欧洲：监管支持与增长

欧洲是神经生物标志物第二大市场，约占全球市场份额的30%。该地区的增长受到医疗投资增加和神经疾病发病率上升的推动。欧洲药品管理局的指导方针等监管框架促进了创新生物标志物的开发和批准，提高了市场的可及性。对精准医疗和以患者为中心的方法的关注也是一个重要的增长驱动因素。该地区的主要国家包括德国、法国和英国，默克和阿斯利康等大型制药公司积极参与生物标志物研究。竞争格局强劲，学术界与行业之间的合作日益增多。成熟的医疗系统和对研究项目的资金支持进一步巩固了神经生物标志物在欧洲的市场地位。

### 亚太地区：快速增长的市场潜力

亚太地区的神经生物标志物市场正在快速增长，约占全球市场份额的20%。该地区的扩张受到医疗支出增加、老龄化人口上升和对神经疾病认识提高的推动。中国和印度等国正在大力投资医疗基础设施和研究，预计将推动对生物标志物的需求。监管机构也越来越支持创新的诊断解决方案，进一步催化市场增长。中国是该地区最大的市场，当地生物技术公司和跨国公司贡献显著。印度正在成为一个关键参与者，专注于神经生物标志物的研究与开发。竞争格局正在演变，当地和国际公司之间的合作增强了创新和市场覆盖。预计这些国家神经疾病的日益普遍将进一步推动市场动态。

### 中东和非洲：未开发的市场机会

中东和非洲地区在神经生物标志物市场逐渐崭露头角，目前约占全球市场份额的5%。增长受到医疗投资增加和神经疾病发病率上升的推动。各国政府开始认识到生物标志物在诊断中的重要性，导致支持性的监管框架的形成。该地区多样化的医疗需求为市场扩展提供了重要机会，特别是在南非和阿联酋等国。南非是该地区的领先市场，越来越重视神经健康的研究与开发。竞争格局由本地和国际参与者的混合构成，合作日益增多，旨在增强诊断能力。尽管关键参与者的存在仍在发展中，但随着意识和医疗可及性的提高，增长潜力是巨大的。

## Competitive Benchmarking

神经生物标志物市场目前的竞争格局动态多变，受到对神经系统疾病早期诊断和个性化治疗方案需求增加的推动。罗氏（瑞士）、艾伯维（美国）和生物科技（美国）等主要参与者在战略上定位，以利用其广泛的研究能力和创新的产品管道。罗氏（瑞士）专注于将先进的诊断与治疗解决方案相结合，而艾伯维（美国）则强调通过合作伙伴关系来增强其生物标志物发现能力。生物科技（美国）则在数字健康技术方面进行了大量投资，以改善患者参与度和数据收集，从而塑造一个优先考虑创新和以患者为中心的方法的竞争环境。

市场结构似乎适度分散，多个参与者通过本地化制造和优化供应链争夺市场份额。公司越来越多地采用提高运营效率和缩短新生物标志物测试上市时间的策略。这种竞争结构允许提供多样化的产品，尽管主要参与者在设定行业标准和推动技术进步方面的影响仍然显著。

在2025年8月，罗氏（瑞士）宣布与一家领先的人工智能公司合作，开发阿尔茨海默病生物标志物的预测模型。这一战略举措可能会增强罗氏在早期诊断方面的能力，使公司处于神经生物标志物领域创新的前沿。将人工智能整合到生物标志物开发中可能会简化研究过程，提高诊断工具的准确性，从而巩固罗氏的竞争优势。

在2025年9月，艾伯维（美国）扩大了与一家知名学术机构的合作，以推进神经退行性疾病的研究。这一合作预计将促进新生物标志物的发现，可能导致治疗方案的突破。通过与学术领袖的对接，艾伯维不仅增强了其研究组合，还促进了一个可能在该领域带来重大进展的创新生态系统。

在2025年7月，生物科技（美国）推出了一个新的数字平台，旨在增强对神经系统疾病患者的监测和数据收集。这一举措反映了生物科技将技术整合到其运营中的承诺，可能改善患者的结果和参与度。该平台旨在收集实时数据，这对完善生物标志物开发和根据个体患者需求量身定制治疗策略可能是无价的。

截至2025年10月，神经生物标志物市场的竞争趋势越来越受到数字化、可持续性和人工智能整合的影响。战略联盟变得越来越普遍，因为公司认识到在应对复杂神经挑战中协作创新的价值。展望未来，竞争差异化似乎将越来越依赖于技术进步和供应链的可靠性，而不仅仅是价格。这一转变表明，创新和战略伙伴关系将在应对神经生物标志物市场不断演变的格局中变得至关重要。

## Recent News & Developments

- **2024年第二季度：Quanterix推出Simoa® p-Tau 217 Advantage V2试剂盒以推进阿尔茨海默病研究** Quanterix宣布推出其Simoa® p-Tau 217 Advantage V2试剂盒，这是一种下一代神经生物标志物检测方法，旨在改善血液样本中阿尔茨海默病病理的检测。
- **2024年第二季度：C2N Diagnostics宣布PrecivityAD2™阿尔茨海默病血液检测获得CE标志** C2N Diagnostics获得了其PrecivityAD2™血液检测的CE标志批准，使其在欧洲的商业推出成为可能，以检测阿尔茨海默病生物标志物。
- **2024年第二季度：Alto Neuroscience在C轮融资中筹集4500万美元以推进精准精神病学平台** Alto Neuroscience在C轮融资中筹集了4500万美元，以加速其针对神经和精神疾病的生物标志物驱动平台的发展。
- **2024年第一季度：Olink推出新的神经生物标志物面板以支持高通量蛋白质组学** Olink推出了新的神经生物标志物面板，扩展其高通量蛋白质组学产品，以支持神经疾病研究和药物开发。
- **2024年第一季度：Neurotrack与Quest Diagnostics宣布战略合作以推进认知衰退的早期检测** Neurotrack与Quest Diagnostics形成合作关系，开发和商业化数字和基于血液的神经生物标志物检测，以便早期检测认知障碍。
- **2024年第二季度：Diadem获得FDA突破性设备认证以用于AlzoSure® Predict阿尔茨海默病血液检测** Diadem宣布其AlzoSure® Predict血液检测用于早期检测阿尔茨海默病获得美国FDA的突破性设备认证。
- **2024年第二季度：Amprion获得FDA突破性设备认证以用于SYNTap生物标志物检测帕金森病** Amprion的SYNTap生物标志物检测旨在检测如帕金森病的突触蛋白病，获得FDA的突破性设备认证。
- **2024年第一季度：Quanterix任命Masoud Toloue为首席执行官** Quanterix宣布任命Masoud Toloue为新任首席执行官，旨在推动神经生物标志物领域的增长。
- **2024年第二季度：Cerveau Technologies与Eisai达成合作以推进Tau PET成像生物标志物研究** Cerveau Technologies与Eisai宣布达成合作，以推进神经退行性疾病的Tau PET成像生物标志物的研究和开发。
- **2024年第一季度：Alzheon宣布获得1亿美元C轮融资以推进ALZ-801和生物标志物项目** Alzheon在C轮融资中筹集了1亿美元，以支持ALZ-801的后期临床开发和其神经生物标志物项目的扩展。
- **2024年第二季度：NeuroSense Therapeutics获得FDA孤儿药认证以用于ALS的PrimeC** NeuroSense Therapeutics获得FDA孤儿药认证，以用于ALS的PrimeC，这一疗法得到了生物标志物驱动的临床开发的支持。
- **2024年第一季度：Alector与GSK宣布战略合作以开发新型神经退行性疾病生物标志物** Alector与GSK达成战略合作，以开发和商业化新型神经退行性疾病生物标志物。

## Report Scope

| 2024年市场规模 | 5.036（十亿美元） |
| --- | --- |
| 2025年市场规模 | 5.3（十亿美元） |
| 2035年市场规模 | 8.833（十亿美元） |
| 复合年增长率（CAGR） | 5.24%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 关键公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 关键市场机会 | 精准医疗的进步增强了神经生物标志物市场的诊断能力。 |
| 关键市场动态 | 对早期诊断的需求上升推动了神经生物标志物开发的创新和监管适应。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 到2035年，神经生物标志物市场的预计市场估值是多少？**
A: 神经生物标志物市场预计到2035年将达到约88.33亿美元。

**Q: 2024年神经生物标志物市场的市场估值是多少？**
A: 2024年，神经生物标志物市场的价值为50.36亿美元。

**Q: 在2025年至2035年的预测期内，神经生物标志物市场的预期CAGR是多少？**
A: 神经生物标志物市场在2025年至2035年预测期内的预期年复合增长率（CAGR）为5.24%。

**Q: 在神经生物标志物市场中，哪些公司被视为关键参与者？**
A: 神经生物标志物市场的主要参与者包括罗氏、艾伯维、生物基因、礼来、诺华、安进、默克、辉瑞和阿斯利康。

**Q: 到2035年，阿尔茨海默病在神经生物标志物市场的预计估值是多少？**
A: 预计到2035年，阿尔茨海默病在神经生物标志物市场的估值将从15亿美元上升至25亿美元。

**Q: 在市场估值方面，基因生物标志物与蛋白质组生物标志物相比如何？**
A: 基因生物标志物预计将从15.09亿美元增长到26.46亿美元，而蛋白质组生物标志物预计将从10.07亿美元增长到17.49亿美元，到2035年。

**Q: 到2035年，神经生物标志物市场中临床实验室的预期市场规模是多少？**
A: 临床实验室的市场规模预计将从10.08亿美元增长到17.5亿美元，到2035年。

**Q: 预计哪些技术进步将影响神经生物标志物市场？**
A: 生物分子分析、成像技术、基因组测序和蛋白质组学的技术进步可能会推动市场增长，预计到2035年估值将显著增加。

**Q: 到2035年，与中风相关的生物标志物的预计市场规模是多少？**
A: 与中风相关的生物标志物市场规模预计将从9亿美元增长到15亿美元，到2035年。

**Q: 神经生物标志物市场的增长在不同应用之间如何比较？**
A: 神经生物标志物市场在各个应用领域的增长差异显著，预计到2035年，阿尔茨海默病和帕金森病将经历最高的估值。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/neurological-biomarker-market-33914*